·SEC EDGARLow
FRANCIS LAURA sold $1.9M of SIBN (indirect holdings)
FRANCIS LAURA (Chief Executive Officer) sold 75,000 indirectly-held shares of SI-BONE, Inc. (SIBN) at $25.30 ($1.90M total) on 2026-11-04 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Medical Devices
$SIBN
SI-BONE, Inc.
SI-BONE develops and sells medical implants and instruments for physicians treating sacroiliac joint dysfunction and degeneration, thoracolumbar fixation and fusion, and pelvic trauma. Its products include titanium implants, implantable bone products and tools used to place them. Product lines include iFuse, iFuse 3D, iFuse TORQ, iFuse Bedrock Granite, iFuse INTRA and iFuse TORQ TNT. The products are used in procedures including sacroiliac joint fusion, spinal fixation and pelvic fracture treatment. SI-BONE sells primarily through its direct sales force and third-party sales agents in the United States, and through direct sales representatives, agents and resellers internationally. It also provides training and education for healthcare professionals on diagnosis and treatment of sacroiliac joint disorders and use of its implants. As of December 31, 2025, its products had been used in over 140,000 procedures since iFuse launched in 2009, and its international sales network reached 38 countries. SI-BONE is headquartered in Santa Clara, California.
AlphAI earnings readThird Quarter 2026 · NOV 2SI-BONE reported third-quarter worldwide revenue growth of 14.5%, improved operating and net losses, positive adjusted EBITDA, and reaffirmed 2026 revenue and gross margin guidance while reducing its operating expense growth expectation.Verdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $SIBNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $SIBN in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $4.0M 6 txs
Maheshwari Anshul2× · $165K
10b5-1 share of filings100%
Top stories · $SIBNMore →
·SEC EDGAR
PISETSKY MICHAEL A. sold $899K of SIBN (indirect holdings)
PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 36,241 indirectly-held shares of SI-BONE, Inc. (SIBN) at $24.80 ($0.90M total) on 2026-11-04 under a Rule 10b5-1 trading plan.
·rttnews.com
Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%
Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.
SIBN sentiment & insider activity
Recent SIBN coverage spans insider activity, financial news and earnings.
In the last 30 days, SIBN insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($4.0M). The most active reporter was Maheshwari Anshul, Chief Op & Financial Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving SIBN
The insider sale may signal confidence concerns, potentially pressuring the stock.
Insider sale of nearly $0.9 M may signal modest downside pressure.
Earnings beat and improved loss guidance likely drive continued buying pressure.
Street PT lift supports near-term sentiment, but it is an analyst action rather than a new company fundamental.
Analyst downgrade may create modest downside pressure, but the new target still suggests upside from current price.
AlphAI scores every news story that mentions SIBN with an AI model for sentiment and relevance, and aggregates insider trades from SI-BONE, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $SIBN
Score
FRANCIS LAURA sold $1.9M of SIBN (indirect holdings)
FRANCIS LAURA (Chief Executive Officer) sold 75,000 indirectly-held shares of SI-BONE, Inc. (SIBN) at $25.30 ($1.90M total) on 2026-11-04 under a Rule 10b5-1 trading plan.
PISETSKY MICHAEL A. sold $899K of SIBN (indirect holdings)
PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 36,241 indirectly-held shares of SI-BONE, Inc. (SIBN) at $24.80 ($0.90M total) on 2026-11-04 under a Rule 10b5-1 trading plan.
Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%
Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.
UBS maintains SI-BONE at Buy, raises price target to $26 from $25
UBS kept its Buy rating on SI-BONE and increased its price target to $26 from $25, suggesting a 28.6% upside from the Nov 2 close of $20.22. Recent analyst price targets for SI-BONE range from $23 to $26.
Needham maintains SI-BONE at Buy, lowers price target to $26 from $27
Needham kept its Buy rating on SI-BONE but reduced its price target from $27 to $26, a 3.7% decrease. This new target suggests a 28.6% upside from the Nov 2 closing price of $20.22.
SI-BONE, Inc. Stock 12‑Month Price Target Raised to $25.78, Implies 27% Upside
Analysts raised SI-BONE, Inc.'s 12-month price target from $25.44 to $25.78, suggesting 27% upside. All 9 analysts maintain a 'Buy' rating. The forecasts range from $23 to $32 per share, based on November 2 closing price.
SI-BONE (SIBN) Q3 2026 Earnings Call Transcript
SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.
SiBone Q3 Earnings Call Highlights
SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.
PISETSKY MICHAEL A. sold $656K of SIBN
PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 29,665 shares of SI-BONE, Inc. (SIBN) at $22.10 ($0.66M total) on 2026-10-29 under a Rule 10b5-1 trading plan.
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance Delivered ~20% U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) • Worldwide